Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: ctDNA is increasingly used to detect minimal residual disease, however, its sensitivity varies by tumor type. Its utility in CCA remains incompletely defined. METHODS: In this single-institution retrospective study, we evaluated ctDNA using a commercial tumor-informed assay (Signatera), compared with CA19-9, for predicting relapse after surgical resection during postoperative (<90 days) and surveillance (≥90 days) windows. We assessed associations between ctDNA status and clinical features, including resection pathology and sites of radiographic relapse. RESULTS: Of 48 patients with CCA who underwent resection between 2020-2025, 26 (54.2%) experienced relapse (median follow-up 18.3 months). ctDNA positivity during both postoperative and surveillance windows was associated with worse median disease-free survival, whereas CA19-9 was not. During the postoperative window, ctDNA sensitivity was 41.7% and specificity was 85.7% for predicting disease relapse any time post-resection. During the surveillance window, sensitivity was 60.0% and specificity was 90.9%. Landmark analysis for relapse at 1-year for ctDNA collected prior to 90 days had a sensitivity of 83.3% and specificity of 90.0%. Among patients with detectable ctDNA who subsequently developed radiographic relapse, median lead time from first ctDNA positivity to relapse was 34 days (IQR 26-132 days), with a maximum lead time of 292 days. ctDNA performance was higher among patients without perineural or lymphovascular invasion and was most frequently positive in those who developed extrahepatic metastases (n = 10/13, 76.9%). CONCLUSIONS: ctDNA is a specific prognostic biomarker that outperforms CA19-9 for predicting relapse after CCA. However, negative ctDNA results should be interpreted cautiously given modest assay sensitivity.
Source: The Oncologist
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
OpenAlex ID: W7236598670
